Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)

Fig. 1

Schematic of the trial design. DMARD disease modifying antirheumatic drugs, ETN etanercept, HCQ hydroxychloroquine, LDA low disease activity, MTX methotrexate, NICE National Institute of Clinical Excellence, RA rheumatoid arthritis, SSZ sulfasalazine, TT treat to target

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us